List of Tables
    Table 1. Pulmonary Arterial Hypertension (PAH) Drugs CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
    Table 2. Pulmonary Arterial Hypertension (PAH) Drugs Market Trends
    Table 3. Pulmonary Arterial Hypertension (PAH) Drugs Market Drivers
    Table 4. Pulmonary Arterial Hypertension (PAH) Drugs Market Challenges
    Table 5. Pulmonary Arterial Hypertension (PAH) Drugs Market Restraints
    Table 6. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers in Global Market, Ranking by Revenue (2021)
    Table 11. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Manufacturer, (US$ Million), 2017-2022
    Table 12. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Manufacturer, 2017-2022
    Table 13. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Manufacturer, (K Pcs), 2017-2022
    Table 14. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Manufacturer, 2017-2022
    Table 15. Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Manufacturer (2017-2022) & (USD/Pcs)
    Table 16. Global Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 17. Global Pulmonary Arterial Hypertension (PAH) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Arterial Hypertension (PAH) Drugs as of 2021)
    Table 18. Top Players of Pulmonary Arterial Hypertension (PAH) Drugs in Global Market, Headquarters and Distribution of Producing Region
    Table 19. Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Product Type
    Table 20. Date of International Manufacturers Enter into Pulmonary Arterial Hypertension (PAH) Drugs Market
    Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 22. Top Pulmonary Arterial Hypertension (PAH) Drugs Players in United States Market, Ranking by Revenue (2021)
    Table 23. United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 24. United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Players, 2020, 2021 & 2022
    Table 25. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales by Players, (K Pcs), 2020, 2021 & 2022
    Table 26. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Players, 2020, 2021 & 2022
    Table 27. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 28. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume by Region (2017-2022) & (K Pcs)
    Table 29. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume Forecast by Region (2023-2028) & (K Pcs)
    Table 30. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value by Region (2017-2022) & (US$ Million)
    Table 31. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Forecast by Region (2023-2028) & (US$ Million)
    Table 32. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 33. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 34. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume by Region (2017-2028) & (K Pcs)
    Table 35. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value by Region (2017-2028) & (US$ Million)
    Table 36. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 37. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 38. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 39. Latin Americaa Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 40. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 41. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 42. Pfizer Corporation Information
    Table 43. Pfizer Description and Business Overview
    Table 44. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 45. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product
    Table 46. Pfizer Recent Development
    Table 47. Glaxosmithkline Corporation Information
    Table 48. Glaxosmithkline Description and Business Overview
    Table 49. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 50. Glaxosmithkline Product
    Table 51. Glaxosmithkline Recent Development
    Table 52. Novartis Corporation Information
    Table 53. Novartis Description and Business Overview
    Table 54. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 55. Novartis Product
    Table 56. Novartis Recent Development
    Table 57. United Therapeutics Corporation Information
    Table 58. United Therapeutics Description and Business Overview
    Table 59. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 60. United Therapeutics Product
    Table 61. United Therapeutics Recent Development
    Table 62. AstraZeneca Corporation Information
    Table 63. AstraZeneca Description and Business Overview
    Table 64. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 65. AstraZeneca Product
    Table 66. AstraZeneca Recent Development
    Table 67. Merck Corporation Information
    Table 68. Merck Description and Business Overview
    Table 69. Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 70. Merck Product
    Table 71. Merck Recent Development
    Table 72. Bayer Healthcare Corporation Information
    Table 73. Bayer Healthcare Description and Business Overview
    Table 74. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 75. Bayer Healthcare Product
    Table 76. Bayer Healthcare Recent Development
    Table 77. Actelion Pharmaceuticals Corporation Information
    Table 78. Actelion Pharmaceuticals Description and Business Overview
    Table 79. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 80. Actelion Pharmaceuticals Product
    Table 81. Actelion Pharmaceuticals Recent Development
    Table 82. Daiichi Sankyo Corporation Information
    Table 83. Daiichi Sankyo Description and Business Overview
    Table 84. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 85. Daiichi Sankyo Product
    Table 86. Daiichi Sankyo Recent Development
    Table 87. Northern Therapeutics Corporation Information
    Table 88. Northern Therapeutics Description and Business Overview
    Table 89. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 90. Northern Therapeutics Product
    Table 91. Northern Therapeutics Recent Development
    Table 92. Aires Pharmaceuticals Corporation Information
    Table 93. Aires Pharmaceuticals Description and Business Overview
    Table 94. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 95. Aires Pharmaceuticals Product
    Table 96. Aires Pharmaceuticals Recent Development
    Table 97. Arena Pharmaceuticals Corporation Information
    Table 98. Arena Pharmaceuticals Description and Business Overview
    Table 99. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 100. Arena Pharmaceuticals Product
    Table 101. Arena Pharmaceuticals Recent Development
    Table 102. Berlin Cures Corporation Information
    Table 103. Berlin Cures Description and Business Overview
    Table 104. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 105. Berlin Cures Product
    Table 106. Berlin Cures Recent Development
    Table 107. Eiger BioPharmaceuticals Corporation Information
    Table 108. Eiger BioPharmaceuticals Description and Business Overview
    Table 109. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 110. Eiger BioPharmaceuticals Product
    Table 111. Eiger BioPharmaceuticals Recent Development
    Table 112. Reata Pharmaceuticals Corporation Information
    Table 113. Reata Pharmaceuticals Description and Business Overview
    Table 114. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 115. Reata Pharmaceuticals Product
    Table 116. Reata Pharmaceuticals Recent Development
    Table 117. Key Raw Materials Lists
    Table 118. Raw Materials Key Suppliers Lists
    Table 119. Pulmonary Arterial Hypertension (PAH) Drugs Customers List
    Table 120. Pulmonary Arterial Hypertension (PAH) Drugs Distributors List
    Table 121. Research Programs/Design for This Report
    Table 122. Key Data Information from Secondary Sources
    Table 123. Key Data Information from Primary Sources
List of Figures
    Figure 1. Pulmonary Arterial Hypertension (PAH) Drugs Product Picture
    Figure 2. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size 2017-2028 (US$ Million)
    Figure 4. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales 2017-2028 (K Pcs)
    Figure 5. United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 6. United States Pulmonary Arterial Hypertension (PAH) Drugs Market Size 2017-2028 (US$ Million)
    Figure 7. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales 2017-2028 (K Pcs)
    Figure 8. United States Pulmonary Arterial Hypertension (PAH) Drugs Market Share in Global, in Value (US$ Million) 2017-2028
    Figure 9. United States Pulmonary Arterial Hypertension (PAH) Drugs Market Share in Global, in Volume (K Pcs) 2017-2028
    Figure 10. Pulmonary Arterial Hypertension (PAH) Drugs Report Years Considered
    Figure 11. Product Picture of Inhalation
    Figure 12. Product Picture of Injectables
    Figure 13. Product Picture of Oral Administration
    Figure 14. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Type in 2022 & 2028
    Figure 15. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 16. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Value by Type (2017-2028)
    Figure 17. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2028) & (K Pcs)
    Figure 18. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Volume by Type (2017-2028)
    Figure 19. Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2017-2028) & (USD/Pcs)
    Figure 20. United States Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Type in 2022 & 2028
    Figure 21. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 22. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Value by Type (2017-2028)
    Figure 23. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2028) & (K Pcs)
    Figure 24. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Volume by Type (2017-2028)
    Figure 25. United States Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2017-2028) & (USD/Pcs)
    Figure 26. Product Picture of Hospitals
    Figure 27. Product Picture of Clinics
    Figure 28. Product Picture of Other
    Figure 29. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Application in 2022 & 2028
    Figure 30. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 31. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Value by Application (2017-2028)
    Figure 32. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2028) & (K Pcs)
    Figure 33. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Volume by Application (2017-2028)
    Figure 34. Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2017-2028) & (USD/Pcs)
    Figure 35. United States Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Application in 2022 & 2028
    Figure 36. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 37. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Value by Application (2017-2028)
    Figure 38. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2028) & (K Pcs)
    Figure 39. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Volume by Application (2017-2028)
    Figure 40. United States Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2017-2028) & (USD/Pcs)
    Figure 41. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 42. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 43. U.S. Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Canada Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 46. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 47. Germany Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 48. France Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 49. U.K. Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Italy Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Russia Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 53. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 54. China Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 55. Japan Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 56. South Korea Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 57. India Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 58. Australia Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 59. Taiwan Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 60. Indonesia Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 61. Thailand Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 62. Malaysia Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 63. Philippines Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 64. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 65. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 66. Mexico Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 67. Brazil Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 68. Argentina Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 69. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 70. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 71. Turkey Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 72. Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 73. U.A.E Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 74. Pulmonary Arterial Hypertension (PAH) Drugs Value Chain
    Figure 75. Pulmonary Arterial Hypertension (PAH) Drugs Production Process
    Figure 76. Channels of Distribution
    Figure 77. Distributors Profiles
    Figure 78. Bottom-up and Top-down Approaches for This Report
    Figure 79. Data Triangulation
    Figure 80. Key Executives Interviewed